Skip to main content

Table 1 Patients’ characteristics and treatments before conception

From: Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients

 

RA (n = 75)

axSpA (n = 61)

Age at conception, years (median)

31 (21–40)

31 (22–41)

Age at diagnosis, years (median)

27 (20–38)

24 (17–33)

Rheumatoid factor-positive

50 (66)

HLA-B27-positive

43 (70.5)

axSpA with peripheral arthritis

27 (44.3)

Medication within 3 months before conception

 Methotrexatea

2 (2.7)

 NSAIDs

8 (10.7)

18 (29.5)

 TNFib

15 (20.0)

24 (39.3)

 Glucocorticosteroidsc

25 (33.3)

5 (8.2)

 DMARDs

29 (38.7)

5 (8.2)

  SSZ

18 (24.0)

5 (8.2)

  HCQ

8 (10.7)

 

  SSZ and HCQ

3 (4.0)

 
  1. Abbreviations: axSpA Axial spondyloarthritis, DMARD Disease-modifying antirheumatic drug, HCQ Hydrochloroquine, HLA Human leukocyte antigen, NSAID Nonsteroidal anti-inflammatory drug, RA Rheumatoid arthritis, SSZ Sulfasalazine, TNFi Tumor necrosis factor inhibitor
  2. aMethotrexate, discontinued 1 month before the planned conception
  3. bTNFi, discontinued at the time of the positive pregnancy test
  4. cPrednisone or prednisolone